Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression

Free Radical Biology and Medicine

Volumn 63, Issue , 2013, Pages 187-194

  Rybka, Joanna ^a,e   Kedziora Kornatowska, Kornelia ^b   Banaś Lezańska, Patrycja ^a   Majsterek, Ireneusz ^a   Carvalho, Livia A ^c   Cattaneo, Annamaria ^d   Anacker, Christoph ^d   Kedziora, Józef ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Scienceventure   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Depression; Free radicals; GPx 1; Inflammation; Iron; Macrophage function; MDA; Oxidative stress

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ANTIOXIDANT; COPPER ZINC SUPEROXIDE DISMUTASE; FERRITIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE REDUCTASE; HEME OXYGENASE 1; HEMOGLOBIN; HYDROGEN PEROXIDE; INTERLEUKIN 6; IRON; MALONALDEHYDE; METHEMOGLOBIN; NEOPTERIN; TRANSFERRIN RECEPTOR;

ADULT; ANEMIA; ARTICLE; BLOOD LEVEL; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMET ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DNA DAMAGE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMOLYSATE; HOMEOSTASIS; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

EID: 84879059502     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.05.019     Document Type: Article

References (79)

1. Moylan, S.; Maes, M.; Wray, N. R.; Berk, M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatry 18:595-606; 2012.
2. Berk M.; Kapczinski F.; Andreazza A.C.; Dean O.M.; Giorlando F.; Maes M.; Yücel M.; Gama C.S.; Dodd S.; Dean B.; Magalhães P.V.S.; Amminger P.; McGorry P.; Malhi G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev.35804-817; 2011.
3. Leonard, B.; Maes, M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev 36:764-785; 2012.
4. Maes, M.; Bosmans, E.; Suy, E.; Vandervorst, C.; De Jonckheere, C.; Raus, J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 24:115-120; 1990.
5. Maes, M.; Lambrechts, J.; Bosmans, E.; Jacobs, J.; Suy, E.; Vandervorst, C.; de Jonckheere, C.; Minner, B.; Raus, J. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol. Med. 22:45-53; 1992.
6. Maes, M.; Scharpé, S.; Meltzer, H. Y.; Bosmans, E.; Suy, E. Calabrese J.; Cosyns P. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 49:11-27; 1993. (Pubitemid 23329244)
7. Maes, M.; Scharpé, S.; Meltzer, H. Y.; Okayli, G.; Bosmans, E.; D'Hondt, P.; Vanden Bossche, B. V.; Cosyns, P. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 54:143-160; 1994.
8. Linthorst, A. C.; Reul, J. M. Brain neurotransmission during peripheral inflammation. Ann. N. Y. Acad. Sci 840:139-152; 1998. (Pubitemid 28302045)
9. Maes, M.; Meltzer, H. Y.; Scharpé, S.; Cooreman, W.; Uyttenbroeck, W.; Suy, E.; Vandervorst, C. Calabrese J.; Raus J.; Cosyns P. Psychomotor retardation, anorexia, weight loss, sleep disturbances, and loss of energy: psychopatholo-gical correlates of hyperhaptoglobinemia during major depression. Psychiatry Res. 47:229-241; 1993. (Pubitemid 23190382)
10. Maes, M.; Berk, M.; Goehler, L.; Song, C.; Anderson, G.; Galecki, P.; Leonard, B. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 10:66; 2012.
11. Maes, M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35:664-675; 2011.
12. Murr, C.; Widner, B.; Wirleitner, B.; Fuchs, D. Neopterin as a marker for immune system activation. Curr. Drug Metab 3:175-187; 2002. (Pubitemid 34326529)
13. Murray, P. J.; Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11: 723-737; 2011.
14. Nathan, C.; Ding, A. Nonresolving inflammation. Cell 140:871-882; 2010.
15. Maes, M.; Kubera, M.; Obuchowiczwa, E.; Goehler, L.; Brzeszcz, J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol. Lett 32:7-24; 2011.
16. Maes, M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuroendocrinol. Lett 29:287-291; 2008.
17. Friedman, J. S.; Rebel, V. I.; Derby, R.; Bell, K.; Huang, T. T.; Kuypers, F. A.; Epstein, C. J.; Burakoff, S. J. Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant. J. Exp. Med 193:925-934; 2001. (Pubitemid 32525865)
18. Kanno, H. [Critical role of phosphatidylserine in hemolysis due to red blood cell enzyme/membrane defects]. Nippon Rinsho 66:461-468; 2008.
19. Khandelwal, S.; Saxena, R. K. A role of phosphatidylserine externalization in clearance of erythrocytes exposed to stress but not in eliminating aging populations of erythrocyte in mice. Exp. Gerontol. 43:764-770; 2008.
20. Cambos, M.; Scorza, T. Robust erythrophagocytosis leads to macrophage apoptosis via a hemin-mediated redox imbalance: role in hemolytic disorders. J. Leukocyte Biol 89:159-171; 2010.
21. Sindrilaru, A.; Peters, T.; Wieschalka, S.; Baican, C.; Baican, A.; Peter, H.; Hainzl, A.; Schatz, S.; Qi, Y.; Schlecht, A.; Weiss, J. M.; Wlaschek, M.; Sunderkötter, C.; Scharffetter-Kochanek, K. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Invest. 121:985-997; 2011.
22. Nagababu, E.; Gulyani, S.; Earley, C. J.; Cutler, R. G.; Mattson, M. P.; Rifkind, J. M. Iron-deficiency anaemia enhances red blood cell oxidative stress. Free Radic. Res. 42:824-829; 2008.
23. Lloyd, R. V.; Hanna, P. M.; Mason, R. P. The origin of the hydroxyl radical oxygen in the Fenton reaction. Free Radic. Biol. Med. 22:885-888; 1997. (Pubitemid 27058352)
24. Michalik, V.; Spotheim Maurizot, M.; Charlier, M. Calculation of hydroxyl radical attack on different forms of DNA. J. Biomol. Struct. Dyn 13:565-575; 1995. (Pubitemid 26013706)
25. Gasche, C. Iron, anaemia, and inflammatory bowel diseases. Gut 53:1190-1197; 2004. (Pubitemid 38961976)
26. López-Sierra, M.; Calderón, S.; Gómez, J.; Pilleux, L. Prevalence of anaemia and evaluation of transferrin receptor (sTfR) in the diagnosis of iron deficiency in the hospitalized elderly patients: anaemia clinical studies in Chile. Anemia 2012:1-6; 2012.
27. Wish, J. B. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin. J. Am. Soc. Nephrol. 1:S4-S8; 2006.
28. Koulaouzidis, A.; Said, E.; Cottier, R.; Saeed, A. A. Soluble transferrin receptors and iron deficiency, a step beyond ferritin: a systematic review. J. Gastrointest. Liver Dis 18: 345-352; 2009.
29. Smarr, K. L. Measures of depression and depressive symptoms: the Beck Depression Inventory (BDI), Center for Epidemiological Studies-Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Primary Care Evaluation of Mental Disorders-Mood Module (PRIME-MD). Arthritis Rheum 49:S134-S146; 2003.
30. Beutler, E. Red cell metabolism: a manual of biochemical methods. New York: Grune-Stratton; 1971.
31. Paglia, D. E.; Valentine, W. N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70:158-169; 1967.
32. Flohé, L.; Günzler, W. A. Assays of glutathione peroxidase. Methods Enzymol. 105:114-121; 1984. (Pubitemid 14165378)
33. Misra, H. P.; Fridovich, I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 247:3170-3175; 1972.
34. Chikezie, P. C. Methaemoglobin content and NADH-methaemoglobin reduc-tase activity of three human erythrocyte genotypes. Asian J. Biochem 6:98-103; 2011.
35. Singh, N. P.; McCoy, M. T.; Tice, R. R.; Schneider, E. L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175:184-191; 1988.
36. Doetsch, P. W.; Henner, W. D.; Cunningham, R. P.; Toney, J. H.; Helland, D. E. A highly conserved endonuclease activity present in Escherichia coli, bovine, and human cells recognizes oxidative DNA damage at sites of pyrimidines. Mol. Cell. Biol 7:26-32; 1987. (Pubitemid 17230381)
37. Bilici, M.; Efe, H.; Köroglu, M. A.; Uydu, H. A.; Bekaroglu, M.; Deger, O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J. Affect. Disord. 64:43-51; 2001. (Pubitemid 32268670)
38. Khanzode, S. D.; Dakhale, G. N.; Khanzode, S. S.; Saoji, A.; Palasodkar, R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8:365-370; 2003. (Pubitemid 38128544)
39. Sarandol, A.; Sarandol, E.; Eker, S. S.; Erdinc, S.; Vatansever, E.; Kirli, S. Major depressive disorder is accompanied with oxidative stress: short-term anti-depressant treatment does not alter oxidative-antioxidative systems. Hum. Psychopharmacol 22:67-73; 2007. (Pubitemid 46505714)
40. Herken, H.; Gurel, A.; Selek, S.; Armutcu, F.; Ozen, M. E.; Bulut, M.; Kap, O.; Yumru, M.; Savas, H. A.; Akyol, O. Adenosine deaminase, nitric oxide, super-oxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch. Med. Res. 38:247-252; 2007. (Pubitemid 46080553)
41. Stefanescu, C.; Ciobica, A. The relevance of oxidative stress status in first episode and recurrent depression. J. Affect. Disord. 143:34-38; 2012.
42. Maes, M.; Mihaylova, I.; Kubera, M.; Uytterhoeven, M.; Vrydags, N.; Bosmans, E. Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuroendocrinol. Lett 32:133-140; 2011.
43. Behr, G. A.; Moreira, J. C. F.; Frey, B. N. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophy-siology of major depressive disorder. Oxid. Med. Cell. Longevity 2012:609421; 2012.
44. Janero, D. R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic. Biol. Med 9:515-540; 1990. (Pubitemid 120036914)
45. Siddique, Y. H.; Ara, G.; Afzal, M. Estimation of lipid peroxidation induced by hydrogen peroxide in cultured human lymphocytes. Dose-Response 10:1-10; 2012.
46. Cohen, G.; Hochstein, P. Glutathione peroxidase: the primary agent for the elimination of hydrogen peroxide in erythrocytes. Biochemistry 2:1420-1428; 1963.
47. Kotan, V. O.; Sarandol, E.; Kirhan, E.; Ozkaya, G.; Kirli, S. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog. Neuropsychopharmacol. Biol. Psychiatry 35:1284-1290; 2011.
48. Maes, M.; Mihaylova, I.; Kubera, M.; Uytterhoeven, M.; Vrydags, N.; Bosmans, E. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuroendocrinol. Lett 30:715-722; 2009.
49. Kodydková, J.; Vávrová, L.; Zeman, M.; Jirák, R.; Macásek, J.; Stanková, B.; Tvrzická, E.; Zák, A. Antioxidative enzymes and increased oxidative stress in depressive women. Clin. Biochem. 42:1368-1374; 2009.
50. Schuliga, M.; Chouchane, S.; Snow, E. T. Upregulation of glutathione-related genes and enzyme activities in cultured human cells by sublethal concentrations of inorganic arsenic. Toxicol. Sci 70:183-192; 2002. (Pubitemid 36013651)
51. Gawryluk, J. W.; Wang, J. -F.; Andreazza, A. C; Shao, L.; Young, L. T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 14:123-130; 2011.
52. Altuntas, I.; Aksoy, H.; Coskun, I.; Cayköylü, A.; Akçay, F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin. Chem. Lab. Med 38:1277-1281; 2000. (Pubitemid 32094401)
53. Cumurcu, B. E.; Ozyurt, H.; Etikan, I.; Demir, S.; Karlidag, R. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin. Neurosci. 63:639-645; 2009.
54. Tesoriere, L.; D'Arpa, D.; Butera, D.; Pintaudi, A. M.; Allegra, M.; Livrea, M. A. Exposure to malondialdehyde induces an early redox unbalance preceding membrane toxicity in human erythrocytes. Free Radic. Res 36:89-97; 2002. (Pubitemid 34498553)
55. Jeney, V.; Balla, J.; Yachie, A.; Varga, Z.; Vercellotti, G. M.; Eaton, J. W.; Balla, G. Pro-oxidant and cytotoxic effects of circulating heme. Blood 100:879-887; 2002. (Pubitemid 34832613)
56. Nagy, E.; Jeney, V.; Yachie, A.; Szabó, R. P.; Wagner, O.; Vercellotti, G. M.; Eaton, J. W.; Balla, G.; Balla, J. Oxidation of hemoglobin by lipid hydroperoxide associated with low-density lipoprotein (LDL) and increased cytotoxic effect by LDL oxidation in heme oxygenase-1 (HO-1) deficiency. Cell. Mol. Biol. (Noisy-le-grand) 51:377-385; 2005. (Pubitemid 41596315)
57. Maes, M.; Mihaylova, I.; Kubera, M.; Ringel, K. Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 36:169-175; 2012.
58. Berk, M.; Wadee, A. A.; Kuschke, R. H.; O'Neill-Kerr, A. Acute phase proteins in major depression. J. Psychosom. Res. 43:529-534; 1997. (Pubitemid 27487544)
59. Karlovic, D.; Serretti, A.; Vrkic, N.; Martinac, M.; Marcinko, D. Serum concentrations of CRP, IL-6, TNF-oc and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res 198:74-80; 2012.
60. Koutsouraki, E.; Hatzifilipou, E.; Michmizos, D.; Cotsavasiloglou, C; Costa, V.; Baloyannis, S. Increase in interleukin-6 levels is related to depressive phenomena in the acute (relapsing) phase of multiple sclerosis. J. Neuropsychiatry Clin. Neurosci 23:442-448; 2011.
61. Bob, P.; Raboch, J.; Maes, M.; Susta, M.; Pavlat, J.; Jasova, D.; Vevera, J.; Uhrova, J.; Benakova, H.; Zima, T. Depression, traumatic stress and interleukin-6. J. Affect. Disord. 120:231-234; 2010.
62. Carvalho, L. A.; Torre, J. P.; Papadopoulos, A. S.; Poon, L.; Juruena, M. F.; Markopoulou, K.; Cleare, A. J.; Pariante, C. M. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J. Affect. Disord. 148:136-140; 2012.
63. Cattaneo, A.; Gennarelli, M.; Uher, R.; Breen, G.; Farmer, A.; Aitchison, K. J.; Craig, I. W; Anacker, C; Zunsztain, P. A.; McGuffin, P.; Pariante, C. M. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline "predictors" and longitudinal "targets.". Neuropsychopharmacology 38:377-385; 2013.
64. Haack, M.; Hinze-Selch, D.; Fenzel, T.; Kraus, T.; Kühn, M.; Schuld, A.; Pollmächer, T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res 33:407-418; 1999. (Pubitemid 29392689)
65. Lanquillon, S.; Krieg, J. C.; Bening-Abu-Shach, U.; Vedder, H. Cytokine production and treatment response in major depressive disorder. Neuropsy-chopharmacology 22:370-379; 2000. (Pubitemid 30105765)
66. Yamada, K.; Iida, R.; Miyamoto, Y.; Saito, K.; Sekikawa, K.; Seishima, M.; Nabeshima, T. Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-alpha gene: implications for emotional behavior. J. Neuroimmunol 111: 131-138; 2000.
67. Kaster, M. P.; Gadotti, V. M.; Calixto, J. B.; Santos, A. R. S.; Rodrigues, A. L. S. Depressive-like behavior induced by tumor necrosis factor-a in mice. Neuro-pharmacology 62:419-426; 2012.
68. Liu, Y.; Ho, R. C. -M.; Mak, A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-a) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J. Affect. Disord 139:230-239; 2012.
69. Miller, A. H.; Maletic, V.; Raison, C. L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65:732-741; 2009.
70. Hannestad, J.; DellaGioia, N.; Bloch, M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36:2452-2459; 2011.
71. Krügel, U.; Fischer, J.; Radicke, S.; Sack, U.; Himmerich, H. Antidepressant effects of TNF-a blockade in an animal model of depression. J. Psychiatr. Res 47:611-616; 2013.
72. Raison, C. L.; Rutherford, R. E.; Woolwine, B. J.; Shuo, C.; Schettler, P.; Drake, D. F.; Haroon, E.; Miller, A. H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31-41; 2013.
73. Wessling-Resnick, M. Iron homeostasis and the inflammatory response. Annu. Rev. Nutr. 30:105-122; 2010.
74. Zarychanski, R.; Houston, D. S. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? Can. Med. Assoc. J. 179:333-337; 2008.
75. Maes, M.; Van de Vyvere, J.; Vandoolaeghe, E.; Bril, T.; Demedts, P.; Wauters, A.; Neels, H. Alterations in iron metabolism and the erythron in major depression: further evidence for a chronic inflammatory process. J. Affect Disord. 40:23-33; 1996. (Pubitemid 26294847)
76. Stewart, R.; Hirani, V. Relationship between depressive symptoms, anemia, and iron status in older residents from a national survey population. Psychosom. Med. 74:208-213; 2012.
77. Baune, B. T.; von Eckardstein, A.; Berger, K. Lack of association between iron metabolism and depressive mood in an elderly general population. Int. Psychogeriatr. 18: 437-444; 2006. (Pubitemid 44131428)
78. Albacar, G.; Sans, T.; Martín-Santos, R.; García-Esteve, L.; Guillamat, R.; Sanjuan, J.; Cañellas, F.; Gratacòs, M.; Cavalle, P.; Arija, V.; Gaviria, A.; Gutiérrez-Zotes, A.; Vilella, E. An association between plasma ferritin concentrations measured 48 h after delivery and postpartum depression. J. Affect Disord. 131:136-142; 2011.
79. Yi, S.; Nanri, A.; Poudel-Tandukar, K.; Nonaka, D.; Matsushita, Y.; Hori, A.; Mizoue, T. Association between serum ferritin concentrations and depressive symptoms in Japanese municipal employees. Psychiatry Res. 189:368-372; 2011.